A Phase II Study to Evaluate the Efficacy of IdeS (IgG Endopeptidase) to Desensitize Transplant Patients With a Positive Crossmatch Test

Trial Profile

A Phase II Study to Evaluate the Efficacy of IdeS (IgG Endopeptidase) to Desensitize Transplant Patients With a Positive Crossmatch Test

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs IdeS (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms HighIdeS
  • Sponsors Hansa Medical AB
  • Most Recent Events

    • 20 Jul 2017 According to a Hansa Medical media release, the company expects to enrol and treat all patients by the end of 2017.
    • 11 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2017.
    • 19 May 2017 According to a Hansa Medical media release, the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) scheme for IdeS. The PRIME designation for IdeS was granted on the basis of data from four independent Phase II studies in the U.S. and Sweden (see CT profiles 269806, 230633, 244081 and 256416).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top